Introduction: Nocturia commonly seen with aging may result from several conditions of which BENIGN PROSTATIC HYPERPLASIA ((BPH)) and loss of nighttime vasopressin production (or release) are very common causes. The relief of obstructive symptoms of (BPH) without addressing the nocturnal polyuria may result in disappointing clinical results. Materials and Methods: A total of adult men (mean age: 62+ /- 2.5 years old) with (BPH) and bothering nocturia (> or = 2voids / night) were treated with oral desmopressin at bedtime. Exclusion criteria included active urinay tract infection, history of myocardial infarction, congestive heart failure, angina and hyponatremia. Patients received desmopressin tablets (0.1,0.2,or 0.4mg ) during a 3 – wk dose titration period and after 1- wk washout period the effective drug dose continued for 6 to 8 – wk . Positive Clinical response defined as > or =50% decrease in nocturnal voiding episodes. Results: All intervened patients improved with such a treatment. The average of symptoms duration was 3.45 +/- 0.62 years. Nocturia episodes decreased from a mean of 4 +/- 0.36 episodes/ night before treatment to1.17 +/- 0.28 episodes/ night after therapy (p< 0.0001). I-PSS decreased from 16.9 +/- 1.16 before treatment to10.47 +/- 0.98 after therapy (p< 0.0001). Serum sodium levels changes were significant (p= 0.02), but hyponatremia did not occur. Also, there was a correlation between age and nocturia episodes (p< 0.0001, r = 0.744. Conclusion: Oral desmopressin tablets provide an effective and well tolerated treatment for nocturia due to (BPH) and cause significant reduction in nocturia episodes; I-PSS measures serum sodium levels with limited side effects.

Background and purposeThe effect of the marker expression high molecular weight cytokeratin (HMWCK (in BENIGN PROSTATIC HYPERPLASIA ((BPH)) and adenocarcinoma prostate. There was conventional reported about rate expression HMWCK in adenocarcinoma prostate. The purpose of this studied was to determine expression of the marker HMWCK with histopathological parameters in (BPH) and adnocarcinoma prostates by immunohistochemistry methods.Materials & Methods: This descriptive analytical research was conducted on 79 patients admitted to Hospital in Isfahan Iran. Samples were fixed in formalin and tissue processing and stained by hematoxilin and eosin adenocarcinoma samples were classified with Gleason pattern (score) method by pathologist. The effect of over expression in marker expression HMWCK was done after diagnosis by two expert (blind). The obtained data were analyzed using chi-square test.Results: Out of the 79 specimens 43 samples were (BPH) and 36 samples were adenocarcinoma.40 samples with diagnosis (BPH) were observed of the marker HMWCK and 3 samples were negative. Out of 36 samples with diagnosis adenocarcinoma, 35 over expression marker of the HMWCK were negative but one samples was positive. The over specimens malignancy were in higher Gleason score. There was significant relationships between type samples ((BPH) and adenocarcinoma) with over expression of the marker HMWCK p<0.001.Conclusion: Our study to showed that usage of the marker HMWCK could be differentiated to increase diagnosis (BPH) tissue from cancer, therefore utilize of the marker HMWCK for prognosis prostate disease could be aided and benefit.

Introduction: We evaluated the efficacy and safety of radiofrequency-induced thermotherapy of the prostate in patients with BENIGN PROSTATIC HYPERPLASIA ((BPH)). Materials and Methods: Radiofrequency-induced thermotherapy of the prostate was performed under local anesthesia in 24 patients (median age, 67 years) with (BPH). The International Prostate Symptom Score (IPSS) score, maximum flow rate, postvoid residual urine volume, and prostate volume were measured preoperatively and 4 months postoperatively. Results: Nine patients (37.5%) had urinary retention preoperatively. One patient (4.2%) required transurethral resection of the prostate due to retention despite improved symptoms and 2 (8.3%) needed an alpha-blocker, postoperatively. The success rate was 87.5% after 4 months follow-up. All patients were catheter-free after the procedure. The mean IPSS score decreased from 26.08 ± 3.9 to 13.33 ±4.69 (P < .001), and the mean maximum flow rate increased from 4.63±4.4 mL/s to 13.21 ± 4.28 mL/s (P < .001). The mean prostate volume and mean residual urine volume were 46.38 ± 16.8 mL and 160±57 mL, which decreased to 39.6±16 mL (P = .009) and 61.46 ± 17.45 mL (P = .003), respectively. Fever, dysuria, and perineal pain (in 9 patients; 37.5%) were improved with conservative therapy. Retrograde ejaculation, erectile dysfunction, and urinary incontinence were not reported. Conclusion: Radiofrequency-induced thermotherapy of the prostate is a new, safe, and effective treatment for (BPH). This technique is carried out under local anesthesia and mild sedation with little bleeding. It is especially appropriate for patients who present as high risk for general anesthesia.

Purpose: Thermobalancing therapy, provided by Therapeutic Device, which contains a natural thermoelement, and is applied topically in the projection ofthe prostate, was aimed to improve blood circulation in the affected organ. We evaluated the effectiveness of new Therapeutic Device for the treatment of patients with BENIGN PROSTATIC HYPERPLASIA ((BPH)). Materials and Methods: We performed a clinical non-randomized controlled trial before and after 6-month treatment. Therapeutic Device was administered to 124 patients with (BPH) as mono-therapy. The dynamic of the patients’ condition was assessed by the International Prostate Symptom Score (IPSS), ultrasound measurement of prostate volume (PV) and uroflowmetry. The control-group comprised 124 men who did not receive any treatment. The IPSS score, maximum flow rate (Qmax), and PV were compared between the groups. Results: Baseline evaluation (pre-treatment) for both groups were comparable to each other with no clinically significant difference regarding age, IPSS score, Qmax and PV volume. Overall, thermobalancing therapy resulted in significant improvements from baseline to endpoint in IPSS (P =. 001), IPSS storage and voiding subscores (both P =. 001), and IPSS quality of life index (QoL) (P =. 001) compared with control group. Moreover, comparison of parameters after 6 months treatment showed that thermobalancing therapy also improved the Qmax (P =. 001), and PV (P =. 001). Conclusion: Two years clinical trial demonstrated that thermobalancing therapy administered for 6 months provides a marked improvement in patients presenting with symptomatic (BPH) not only on lower urinary tract symptoms (LUTS) but also in QoL and Qmax. Thus urologists should be aware about thermobalancing therapy as a non-invasive physiotherapeutic treatment option for treatment of (BPH).